{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T12:54:30Z","timestamp":1787748870220,"version":"build-2784847793"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"Supplement_E","license":[{"start":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T00:00:00Z","timestamp":1591228800000},"content-version":"vor","delay-in-days":73,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inhibitors of the 3-hydroxy-3-methylglutaryl coenzyme A reductase enzyme, statins, are powerful cholesterol-lowering medications and have provided outstanding contributions to the primary and secondary prevention of coronary heart disease. Low-density lipoprotein cholesterol (LDL-C) is one of the major modifiable cardiovascular risk factors, indeed, every 1.0\u2009mmol\/L (38.7\u2009mg\/dL) reduction in LDL cholesterolaemia corresponds to a 21% lowering in the risk of major vascular events. In this context, the pharmacological approach with PCSK9 monoclonal antibodies is considered a promising non-statin therapeutic option for the management of lipid disorders in patients with persistent cardiovascular risk, including patients with diabetes mellitus. Data from two large clinical trials have indisputably demonstrated the efficacy of alirocumab and evolocumab in preventive major adverse cardiovascular events in high risk, secondary-prevention patients with clinical manifestation of atherosclerotic cardiovascular diseases. Finally, PCSK9 monoclonal antibodies did not increase the risk of serious adverse events, neurocognitive events, new-onset of diabetes, muscle-related events, or myalgia.<\/jats:p>","DOI":"10.1093\/eurheartj\/suaa063","type":"journal-article","created":{"date-parts":[[2020,6,4]],"date-time":"2020-06-04T09:12:30Z","timestamp":1591261950000},"page":"E64-E67","source":"Crossref","is-referenced-by-count":11,"title":["Proprotein convertase subtilisin\/kexin type 9: an update on the cardiovascular outcome studies"],"prefix":"10.1093","volume":"22","author":[{"given":"Nicola","family":"Ferri","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze del Farmaco, Universit\u00e0 degli Studi di Padova, Padua, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Francesca","family":"Greco","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmacologiche e Biomolecolari, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Corsini","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmacologiche e Biomolecolari, Universit\u00e0 degli Studi di Milano, Milan, Italy"},{"name":"Multimedica IRCCS, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Ruscica","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Farmacologiche e Biomolecolari, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,23]]},"reference":[{"key":"2021030207161237100_suaa063-B1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1038\/nature10146","article-title":"Progress and challenges in translating the biology of atherosclerosis","volume":"473","author":"Libby","year":"2011","journal-title":"Nature"},{"key":"2021030207161237100_suaa063-B2","doi-asserted-by":"crossref","first-page":"2631","DOI":"10.1016\/j.jacc.2012.09.017","article-title":"Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis","volume":"60","author":"Ference","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"2021030207161237100_suaa063-B3","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.jacc.2014.02.615","article-title":"Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials","volume":"64","author":"Boekholdt","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"2021030207161237100_suaa063-B4","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"key":"2021030207161237100_suaa063-B5","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14712598.2017.1330849","article-title":"Bococizumab for the treatment of hypercholesterolaemia","volume":"17","author":"Ferri","year":"2017","journal-title":"Expert Opin Biol Ther"},{"key":"2021030207161237100_suaa063-B6","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1016\/S0140-6736(17)32290-0","article-title":"Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial","volume":"390","author":"Giugliano","year":"2017","journal-title":"Lancet"},{"key":"2021030207161237100_suaa063-B7","article-title":"PCSK9 inhibitors: clinical evidence and implementation","author":"Sabatine","year":"2018","journal-title":"Nat Rev Cardiol"},{"key":"2021030207161237100_suaa063-B8","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1089\/ars.2014.6054","article-title":"Hemodynamic shear stress via ROS modulates PCSK9 expression in human vascular endothelial and smooth muscle cells and along the mouse aorta","volume":"22","author":"Ding","year":"2015","journal-title":"Antioxid Redox Signal"},{"key":"2021030207161237100_suaa063-B9","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.atherosclerosis.2016.07.910","article-title":"PCSK9 knock-out mice are protected from neointimal formation in response to perivascular carotid collar placement","volume":"253","author":"Ferri","year":"2016","journal-title":"Atherosclerosis"},{"key":"2021030207161237100_suaa063-B10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.atherosclerosis.2016.03.010","article-title":"PCSK9 in relation to coronary plaque inflammation: results of the ATHEROREMO-IVUS study","volume":"248","author":"Cheng","year":"2016","journal-title":"Atherosclerosis"},{"key":"2021030207161237100_suaa063-B11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005764","article-title":"Circulating levels of proprotein convertase subtilisin\/kexin type 9 and arterial stiffness in a large population sample: data from the Brisighella Heart Study","volume":"6","author":"Ruscica","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2021030207161237100_suaa063-B12","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jacc.2017.11.069","article-title":"PCSK9 as a positive modulator of platelet activation","volume":"71","author":"Camera","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021030207161237100_suaa063-B13","doi-asserted-by":"crossref","first-page":"2267.","DOI":"10.1038\/s41598-018-20425-x","article-title":"PCSK9 induces a pro-inflammatory response in macrophages","volume":"8","author":"Ricci","year":"2018","journal-title":"Sci Rep"},{"key":"2021030207161237100_suaa063-B14","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2018.09.063","article-title":"PCSK9 involvement in aortic valve calcification","author":"Poggio","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021030207161237100_suaa063-B15","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.cjca.2018.04.002","article-title":"Cardiovascular efficacy and safety of pcsk9 inhibitors: systematic review and meta-analysis including the ODYSSEY OUTCOMES trial","volume":"34","author":"Turgeon","year":"2018","journal-title":"Can J Cardiol"},{"key":"2021030207161237100_suaa063-B16","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1056\/NEJMoa1801174","article-title":"Alirocumab and cardiovascular outcomes after acute coronary syndrome","volume":"379","author":"Schwartz","year":"2018","journal-title":"N Engl J Med"},{"key":"2021030207161237100_suaa063-B17","article-title":"Alirocumab reduces total nonfatal cardiovascular and fatal events in the ODYSSEY OUTCOMES trial","author":"Szarek","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2021030207161237100_suaa063-B18","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-8587(17)30313-3","article-title":"Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial","volume":"5","author":"Sabatine","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2021030207161237100_suaa063-B19","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1161\/CIRCULATIONAHA.118.034309","article-title":"Clinical benefit of evolocumab by severity and extent of coronary artery disease","volume":"138","author":"Sabatine","year":"2018","journal-title":"Circulation"},{"key":"2021030207161237100_suaa063-B20","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1161\/CIRCULATIONAHA.117.032235","article-title":"Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)","volume":"137","author":"Bonaca","year":"2018","journal-title":"Circulation"},{"key":"2021030207161237100_suaa063-B21","article-title":"Inflammatory and cholesterol risk in the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Patients With Elevated Risk)","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"2021030207161237100_suaa063-B22","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"key":"2021030207161237100_suaa063-B23","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"2021030207161237100_suaa063-B24","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"2021030207161237100_suaa063-B25","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","author":"Ference","year":"2017","journal-title":"Eur Heart J"},{"key":"2021030207161237100_suaa063-B26","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1161\/CIRCULATIONAHA.118.034942","article-title":"Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment","volume":"138","author":"Sliz","year":"2018","journal-title":"Circulation"}],"container-title":["European Heart Journal Supplements"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_E\/E64\/36413277\/suaa063.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/eurheartjsupp\/article-pdf\/22\/Supplement_E\/E64\/36413277\/suaa063.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,2]],"date-time":"2021-03-02T07:16:33Z","timestamp":1614669393000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartjsupp\/article\/22\/Supplement_E\/E64\/5851024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,23]]},"references-count":26,"journal-issue":{"issue":"Supplement_E","published-online":{"date-parts":[[2020,3,23]]},"published-print":{"date-parts":[[2020,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/suaa063","relation":{},"ISSN":["1520-765X","1554-2815"],"issn-type":[{"value":"1520-765X","type":"print"},{"value":"1554-2815","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,3,23]]}}}